{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:25:16Z","timestamp":1793946316432,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ajo.2026.03.042","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:07:05Z","timestamp":1775689625000},"page":"222-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Optogenetic Therapy With UGX-201 in Advanced Nonsyndromic Retinitis Pigmentosa: Safety and Efficacy From an Exploratory Clinical Trial"],"prefix":"10.1016","volume":"287","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2328-4363","authenticated-orcid":false,"given":"Xue","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1728-7904","authenticated-orcid":false,"given":"Gaoqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-2065","authenticated-orcid":false,"given":"Xue","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfa","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peirong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.03.042_bib0001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.preteyeres.2018.03.005","article-title":"Non-syndromic retinitis pigmentosa","volume":"66","author":"Verbakel","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"1-2","key":"10.1016\/j.ajo.2026.03.042_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cccn.2004.08.004","article-title":"Gene mutations in retinitis pigmentosa and their clinical implications","volume":"351","author":"Wang","year":"2005","journal-title":"Clin Chim Acta"},{"issue":"9","key":"10.1016\/j.ajo.2026.03.042_bib0003","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.3390\/ijms23094883","article-title":"Retinitis pigmentosa: progress in molecular pathology and biotherapeutical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajo.2026.03.042_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/737053","article-title":"Systematic review of randomized clinical trials on safety and efficacy of pharmacological and nonpharmacological treatments for retinitis pigmentosa","volume":"2015","author":"Sacchetti","year":"2015","journal-title":"J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2026.03.042_bib0005","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaophthalmol.2018.1171","article-title":"Effect of oral valproic acid vs placebo for vision loss in patients with autosomal dominant retinitis pigmentosa: a randomized phase 2 multicenter placebo-controlled clinical trial","volume":"136","author":"Birch","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2026.03.042_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.847910","article-title":"NUTRARET: effect of 2-year nutraceutical supplementation on redox status and visual function of patients with retinitis pigmentosa: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Olivares-Gonz\u00e1lez","year":"2022","journal-title":"Front Nutr"},{"issue":"10097","key":"10.1016\/j.ajo.2026.03.042_bib0007","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ajo.2026.03.042_bib0008","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.042_bib0009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum Genet"},{"key":"10.1016\/j.ajo.2026.03.042_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2024.05.034","article-title":"Phase 1\/2 AAV5-hRKp.RPGR (botaretigene sparoparvovec) gene therapy: safety and efficacy in RPGR-associated X-linked retinitis pigmentosa","volume":"267","author":"Michaelides","year":"2024","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.03.042_bib0011","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/archopht.1997.01100150513011","article-title":"Preservation of the inner retina in retinitis pigmentosa. A morphometric analysis","volume":"115","author":"Santos","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"23","key":"10.1016\/j.ajo.2026.03.042_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315041","article-title":"Optogenetic therapy for visual restoration","volume":"23","author":"Sakai","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ajo.2026.03.042_bib0013","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.conb.2011.06.001","article-title":"Optogenetic approaches to restoring visual function in retinitis pigmentosa","volume":"21","author":"Busskamp","year":"2011","journal-title":"Curr Opin Neurobiol"},{"issue":"31","key":"10.1016\/j.ajo.2026.03.042_bib0014","doi-asserted-by":"crossref","first-page":"eadg8163","DOI":"10.1126\/sciadv.adg8163","article-title":"Inducible nonhuman primate models of retinal degeneration for testing end-stage therapies","volume":"9","author":"Ail","year":"2023","journal-title":"Sci Adv"},{"issue":"7","key":"10.1016\/j.ajo.2026.03.042_bib0015","doi-asserted-by":"crossref","first-page":"e3720","DOI":"10.1002\/jgm.3720","article-title":"Safety of intravitreally delivered AAV2 vector-mediated multi-characteristic opsin genetic construct in wild type beagle dogs","volume":"26","author":"Mohanty","year":"2024","journal-title":"J Gene Med"},{"issue":"7","key":"10.1016\/j.ajo.2026.03.042_bib0016","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/s41591-021-01351-4","article-title":"Partial recovery of visual function in a blind patient after optogenetic therapy","volume":"27","author":"Sahel","year":"2021","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ajo.2026.03.042_bib0017","first-page":"1106","article-title":"Optogenetics in the clinic: safety and efficacy updates on the phase 1\/2 clinical trial PIONEER","volume":"63","author":"Sahel","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2026.03.042_bib0018","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.ymthe.2025.03.031","article-title":"A synthetic opsin restores vision in patients with severe retinal degeneration","volume":"33","author":"Mohanty","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2026.03.042_bib0019","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s42003-022-04016-1","article-title":"Bipolar cell targeted optogenetic gene therapy restores parallel retinal signaling and high-level vision in the degenerated retina","volume":"5","author":"Kralik","year":"2022","journal-title":"Commun Biol"},{"issue":"21","key":"10.1016\/j.ajo.2026.03.042_bib0020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111515","article-title":"Functional availability of ON-bipolar cells in the degenerated retina: timing and longevity of an optogenetic gene therapy","volume":"22","author":"Kralik","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ajo.2026.03.042_bib0021","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-024-01806-3","article-title":"Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ajo.2026.03.042_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41433-023-02636-3","article-title":"Full-field stimulus threshold testing: a scoping review of current practice","volume":"38","author":"Shi","year":"2024","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.042_bib0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10633-009-9204-7","article-title":"Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the diagnosys full-field stimulus threshold (D-FST)","volume":"119","author":"Klein","year":"2009","journal-title":"Doc Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2026.03.042_bib0024","doi-asserted-by":"crossref","first-page":"N51","DOI":"10.1088\/0967-3334\/28\/8\/N02","article-title":"Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials","volume":"28","author":"Roman","year":"2007","journal-title":"Physiol Meas"},{"key":"10.1016\/j.ajo.2026.03.042_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.101000","article-title":"Full-field stimulus testing: role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease","volume":"87","author":"Roman","year":"2022","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.ajo.2026.03.042_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100133","article-title":"Restoration of cone sensitivity to individuals with congenital photoreceptor blindness within the phase 1\/2 Sepofarsen trial","volume":"2","author":"Cideciyan","year":"2022","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2026.03.042_bib0027","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.03.042_bib0028","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/eye.2015.3","article-title":"The Royal College of Ophthalmologists\u2019 National Ophthalmology Database Study of Cataract Surgery: report 1, visual outcomes and complications","volume":"29","author":"Day","year":"2015","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2026.03.042_bib0029","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3390\/ph16060791","article-title":"Recently approved drugs for lowering and controlling intraocular pressure to reduce vision loss in ocular hypertensive and glaucoma patients","volume":"16","author":"Sharif","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"23","key":"10.1016\/j.ajo.2026.03.042_bib0030","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1097\/BRS.0b013e318158cc23","article-title":"Changes in intraocular pressure due to surgical positioning: studying potential risk for postoperative vision loss","volume":"32","author":"Walick","year":"2007","journal-title":"Spine (Phila Pa 1976)"},{"issue":"1","key":"10.1016\/j.ajo.2026.03.042_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ajo.2026.03.042_bib0032","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ajo.2026.03.042_bib0033","first-page":"665","article-title":"Stargardt\u2019s pigmentosa: a novel combination of two inherited retinal dystrophies","volume":"98","author":"Bartol-Puyal","year":"2023","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.042_bib0034","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1080\/08820538.2021.1957126","article-title":"Clinical presentation and demographic distribution of retinitis pigmentosa in India and implications for potential treatments: electronic medical records driven big data analytics: report I","volume":"37","author":"Parameswarappa","year":"2022","journal-title":"Semin Ophthalmol"},{"issue":"15","key":"10.1016\/j.ajo.2026.03.042_bib0035","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167546","article-title":"Natural history of retinitis pigmentosa based on genotype, vitamin A\/E supplementation, and an electroretinogram biomarker","volume":"8","author":"Comander","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.ajo.2026.03.042_bib0036","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/0042-6989(87)90025-3","article-title":"Dependence of cone b-wave implicit time on rod amplitude in retinitis pigmentosa","volume":"27","author":"Birch","year":"1987","journal-title":"Vision Res"},{"issue":"1","key":"10.1016\/j.ajo.2026.03.042_bib0037","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41467-019-09124-x","article-title":"Restoration of high-sensitivity and adapting vision with a cone opsin","volume":"10","author":"Berry","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajo.2026.03.042_bib0038","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9-10","key":"10.1016\/j.ajo.2026.03.042_bib0039","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41434-024-00477-7","article-title":"The AAV2.7m8 capsid packages a higher degree of heterogeneous vector genomes than AAV2","volume":"31","author":"Cui","year":"2024","journal-title":"Gene Ther"},{"key":"10.1016\/j.ajo.2026.03.042_bib0040","first-page":"1540","article-title":"Gamma-synuclein as a marker of retinal ganglion cells","volume":"14","author":"Surgucheva","year":"2008","journal-title":"Mol Vis"},{"issue":"10045","key":"10.1016\/j.ajo.2026.03.042_bib0041","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"issue":"9549","key":"10.1016\/j.ajo.2026.03.042_bib0042","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.042_bib0043","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for Leber hereditary optic neuropathy: initial results","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.03.042_bib0044","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.ajo.2026.03.042_bib0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/ceo.12547","article-title":"Chemical and material communication between the optic nerves in rats","volume":"43","author":"Yang","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.03.042_bib0046","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41593-017-0029-5","article-title":"Single-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex","volume":"21","author":"Hrvatin","year":"2017","journal-title":"Nat Neurosci"},{"issue":"6","key":"10.1016\/j.ajo.2026.03.042_bib0047","first-page":"767","article-title":"Residual vision activation and the brain-eye-vascular triad: dysregulation, plasticity and restoration in low vision and blindness\u2014a review","volume":"36","author":"Sabel","year":"2018","journal-title":"Restor Neurol Neurosci"},{"issue":"8","key":"10.1016\/j.ajo.2026.03.042_bib0048","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/tvst.9.8.25","article-title":"Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the International HOVER taskforce","volume":"9","author":"Ayton","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"5990","key":"10.1016\/j.ajo.2026.03.042_bib0049","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.1194086","article-title":"Neuroscience. Seeing the light of day","volume":"329","author":"Cepko","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ajo.2026.03.042_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101089","article-title":"Optogenetics for visual restoration: from proof of principle to translational challenges","volume":"91","author":"Lindner","year":"2022","journal-title":"Prog Retin Eye Res"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426001716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426001716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:27:39Z","timestamp":1793942859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426001716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"alternative-id":["S0002939426001716"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.03.042","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optogenetic Therapy With UGX-201 in Advanced Nonsyndromic Retinitis Pigmentosa: Safety and Efficacy From an Exploratory Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.03.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}